Former Valeant Pharmaceuticals International Inc Chief Executive Michael Pearson has filed a lawsuit against the Canadian drugmaker, alleging it refused to pay him more than 3 million shares he is owed, the Wall Street Journal reported on Monday.
Based on Valeant's stock price of $10.81 at the close of trading Monday on the NYSE, the shares have a market value of about $32.43 million. READ MORE